25-Hydroxyvitamin Levels in Sjögren’s Syndrome: Is It the Right Time to Dismiss the Case or Not
| dc.contributor.author | Sımsır, Ilgın Yıldırım | |
| dc.contributor.author | Tanigor, Goksel | |
| dc.contributor.author | Karabulut, Gonca | |
| dc.contributor.author | Barutcuoglu, Burcu | |
| dc.contributor.author | Yılmaz, Zevcet | |
| dc.date.accessioned | 2024-10-25T15:17:46Z | |
| dc.date.available | 2024-10-25T15:17:46Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | Objectives: This study aimed to investigate whether patients with primary Sjögren syndrome (SjS) have different levels of 25 OH-D3 (vitamin D) when compared to healthy populations and whether differences in 25 OH-D3 correlated with disease activity or markers. Methods: Eighty-eight female patients with SjS and 3,338 age-matched healthy female controls were included in this study. 25 OH-D3 levels were compared with healthy controls. Then the patients were stratified according to their 25 OH-D3 levels, either insufficient/deficient or normal (<50 nmol/L or ≥50 nmol/L). The disease activity was evaluated using The EULAR SjS disease activity index (ESSDAI) and its components. Correlation analyses were also performed for a possible correlation with disease characteristics and markers of activity. Results: No differences in 25 OH-D3 levels were found between SjS and healthy populations (p>0.05). No correla- tions were found between patient characteristics or labo- ratory values (p>0.05). Conclusions: This study did not find a link between disease characteristics and disease activity and 25 OH-D3 levels. Prospective studies with more patients should be conducted to reach a conclusion. | en_US |
| dc.identifier.doi | 10.1515/tjb-2023-0273 | |
| dc.identifier.issn | 1303-829X | |
| dc.identifier.issn | 1303-829X | |
| dc.identifier.scopus | 2-s2.0-85205147173 | |
| dc.identifier.uri | https://doi.org/10.1515/tjb-2023-0273 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14365/5554 | |
| dc.identifier.uri | https://search.trdizin.gov.tr/en/yayin/detay/1359172/25-hydroxyvitamin-d-levels-in-sjogrens-syndrome-is-it-the-right-time-to-dismiss-the-case-or-not | |
| dc.language.iso | en | en_US |
| dc.publisher | Walter de Gruyter GmbH | en_US |
| dc.relation.ispartof | Turkish Journal of Biochemistry-Turk Biyokimya Dergisi | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | 25 OH-D3 Levels | en_US |
| dc.subject | Disease Activity | en_US |
| dc.subject | Sjögren Syndrome | en_US |
| dc.subject | Vitamin D | en_US |
| dc.subject | Primary Sjögren's-Syndrome | en_US |
| dc.subject | Vitamin-D Levels | en_US |
| dc.subject | Disease-Activity | en_US |
| dc.subject | Association | en_US |
| dc.subject | Deficiency | en_US |
| dc.subject | Essdai | en_US |
| dc.title | 25-Hydroxyvitamin Levels in Sjögren’s Syndrome: Is It the Right Time to Dismiss the Case or Not | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.institutional | Tanıgör, Göksel | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C5 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
| gdc.description.departmenttemp | Ege Üniversitesi,İzmir Ekonomi Üniversitesi,Ege Üniversitesi,Ege Üniversitesi,Sağlık Bilimleri Üniversitesi | en_US |
| gdc.description.endpage | 726 | |
| gdc.description.endpage | 726 | en_US |
| gdc.description.issue | 6 | en_US |
| gdc.description.publicationcategory | Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q4 | |
| gdc.description.startpage | 721 | |
| gdc.description.startpage | 721 | en_US |
| gdc.description.volume | 49 | |
| gdc.description.volume | 49 | en_US |
| gdc.description.woscitationindex | Science Citation Index Expanded | |
| gdc.description.wosquality | Q4 | |
| gdc.identifier.openalex | W4402677067 | |
| gdc.identifier.trdizinid | 1359172 | |
| gdc.identifier.wos | WOS:001317193600001 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | TR-Dizin | |
| gdc.oaire.accesstype | GOLD | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 1.0 | |
| gdc.oaire.influence | 2.532519E-9 | |
| gdc.oaire.isgreen | false | |
| gdc.oaire.keywords | Sonstiges | |
| gdc.oaire.keywords | sjögren syndrome | |
| gdc.oaire.keywords | 330 | |
| gdc.oaire.keywords | Naturwissenschaften | |
| gdc.oaire.keywords | vitamin d | |
| gdc.oaire.keywords | QD415-436 | |
| gdc.oaire.keywords | disease activity | |
| gdc.oaire.keywords | Biochemistry | |
| gdc.oaire.keywords | 25 oh-d3 levels | |
| gdc.oaire.popularity | 3.125517E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.openalex.collaboration | International | |
| gdc.openalex.fwci | 0.3395 | |
| gdc.openalex.normalizedpercentile | 0.63 | |
| gdc.opencitations.count | 0 | |
| gdc.plumx.crossrefcites | 1 | |
| gdc.plumx.mendeley | 2 | |
| gdc.plumx.scopuscites | 1 | |
| gdc.scopus.citedcount | 1 | |
| gdc.virtual.author | Tanıgör, Göksel | |
| gdc.wos.citedcount | 1 | |
| relation.isAuthorOfPublication | 67235d4c-3cc7-4491-ba73-f319cf56ab8b | |
| relation.isAuthorOfPublication.latestForDiscovery | 67235d4c-3cc7-4491-ba73-f319cf56ab8b | |
| relation.isOrgUnitOfPublication | 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd | |
| relation.isOrgUnitOfPublication | fbc53f3e-d1d3-4168-afd8-e42cd20bddd9 | |
| relation.isOrgUnitOfPublication | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd |
